 |
|
Effect of Different Antilipidemic Agents and Diets on Mortality
A Systematic Review
Marco Studer, MD;
Matthias Briel, MD;
Bernd Leimenstoll, MD;
Tracy R. Glass, MSc;
Heiner C. Bucher, MD, MPH
Arch Intern Med. 2005;165:725-730.
Background Guidelines for the prevention and treatment of hyperlipidemia are often based on trials using combined clinical end points. Mortality data are the most reliable data to assess efficacy of interventions. We aimed to assess efficacy and safety of different lipid-lowering interventions based on mortality data.
Methods We conducted a systematic search of randomized controlled trials published up to June 2003, comparing any lipid-lowering intervention with placebo or usual diet with respect to mortality. Outcome measures were mortality from all, cardiac, and noncardiovascular causes.
Results A total of 97 studies met eligibility criteria, with 137 140 individuals in intervention and 138 976 individuals in control groups. Compared with control groups, risk ratios for overall mortality were 0.87 for statins (95% confidence interval [CI], 0.81-0.94), 1.00 for fibrates (95% CI, 0.91-1.11), 0.84 for resins (95% CI, 0.66-1.08), 0.96 for niacin (95% CI, 0.86-1.08), 0.77 for n-3 fatty acids (95% CI, 0.63-0.94), and 0.97 for diet (95% CI, 0.91-1.04). Compared with control groups, risk ratios for cardiac mortality indicated benefit from statins (0.78; 95% CI, 0.72-0.84), resins (0.70; 95% CI, 0.50-0.99) and n-3 fatty acids (0.68; 95% CI, 0.52-0.90). Risk ratios for noncardiovascular mortality of any intervention indicated no association when compared with control groups, with the exception of fibrates (risk ratio, 1.13; 95% CI, 1.01-1.27).
Conclusions Statins and n-3 fatty acids are the most favorable lipid-lowering interventions with reduced risks of overall and cardiac mortality. Any potential reduction in cardiac mortality from fibrates is offset by an increased risk of death from noncardiovascular causes.
Author Affiliations: Basel Institute for Clinical Epidemiology (Drs Studer, Briel, and Bucher and Ms Glass) and Department of Internal Medicine (Drs Studer and Leimenstoll), University Hospital Basel, Basel, Switzerland.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study
Svensson et al.
Nephrol Dial Transplant 2008;0:gfn180v1-gfn180.
ABSTRACT
| FULL TEXT
Hypertriglyceridemia.
Oh et al.
NEJM 2008;358:310-310.
FULL TEXT
State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health
O'Neil and Nicklas
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:457-481.
ABSTRACT
Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study
Lok et al.
Clin Trials 2007;4:357-367.
ABSTRACT
Do Statins Reduce Blood Pressure?: A Meta-Analysis of Randomized, Controlled Trials
Strazzullo et al.
Hypertension 2007;49:792-798.
ABSTRACT
| FULL TEXT
Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia
McKenney and Sica
Am J Health Syst Pharm 2007;64:595-605.
ABSTRACT
| FULL TEXT
The Triglyceride-Lowering Effects of a Modest Dose of Docosahexaenoic Acid Alone Versus in Combination with Low Dose Eicosapentaenoic Acid in Patients with Coronary Artery Disease and Elevated Triglycerides
Schwellenbach et al.
J. Am. Coll. Nutr. 2006;25:480-485.
ABSTRACT
| FULL TEXT
The Fish in Secondary Prevention of Heart Disease (FISH) Survey--Primary Care Physicians and {omega}3 Fatty Acid Prescribing Behaviors
Oh et al.
J Am Board Fam Med 2006;19:459-467.
ABSTRACT
| FULL TEXT
Interventions Need to Be Consistent With Osteopathic Philosophy
Vasquez
JAOA: Journal of the American Osteopathic Association 2006;106:528-529.
FULL TEXT
Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch
CJASN 2006;1:1090-1099.
ABSTRACT
| FULL TEXT
N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: A Randomized, Placebo-Controlled Intervention Trial
Svensson et al.
CJASN 2006;1:780-786.
ABSTRACT
| FULL TEXT
Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk
El Fakiri et al.
Heart 2006;92:741-745.
ABSTRACT
| FULL TEXT
Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
Briel et al.
JAMA 2006;295:2046-2056.
ABSTRACT
| FULL TEXT
The Seattle Heart Failure Model: Prediction of Survival in Heart Failure
Levy et al.
Circulation 2006;113:1424-1433.
ABSTRACT
| FULL TEXT
Overweight and Increased Cardiovascular Mortality: No French Paradox
Hu
Hypertension 2005;46:645-646.
FULL TEXT
The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT
| FULL TEXT
|
